The “Liquid Biopsy”: the Role of Circulating DNA and RNA in Central Nervous System Tumors

Current Neurology and Neuroscience Reports

Volumn 16, Issue 3, 2016, Pages 1-8

  Connolly, Ian D ^a,b   Li, Yingmei ^a,b   Gephart, Melanie Hayden ^a,b   Nagpal, Seema ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Brain tumor; cfDNA; Circulating tumor cells; Liquid biopsy; miRNA

Indexed keywords

CELL FREE DNA; DNA; GENOMIC DNA; MITOCHONDRIAL DNA; NESTIN; NUCLEIC ACID; RNA; UNCLASSIFIED DRUG; TUMOR MARKER;

BLOOD BRAIN BARRIER; BODY FLUID; CELL FREE SYSTEM; CELL ISOLATION; CELL SEARCH SYSTEM; CENTRAL NERVOUS SYSTEM TUMOR; CEREBROSPINAL FLUID ANALYSIS; CIRCULATING TUMOR CELL; DIAGNOSTIC ACCURACY; HIGH THROUGHPUT SEQUENCING; HUMAN; IMMUNOFLUORESCENCE TEST; LIQUID BIOPSY; METASTASIS; MORBIDITY; NEXT GENERATION SEQUENCING; POLYMERASE CHAIN REACTION; PROTEIN BLOOD LEVEL; REVIEW; SENSITIVITY AND SPECIFICITY; SEPARATION TECHNIQUE; TUMOR BIOPSY; TUMOR DIAGNOSIS; CHEMISTRY; GENETICS;

BIOMARKERS, TUMOR; CELL-FREE SYSTEM; CENTRAL NERVOUS SYSTEM NEOPLASMS; DNA, MITOCHONDRIAL; DNA, NEOPLASM; HUMANS; RNA;

EID: 84957605493     PISSN: 15284042     EISSN: 15346293     Source Type: Journal    
DOI: 10.1007/s11910-016-0629-6     Document Type: Review

References (58)

1. Rowley AH, Whitley RJ, Lakeman FD, Wolinksy SM. Rapid detection of herpes-simplex-virus DNA in cerebrospinal fluid of patients with herpes simplex encephalitis method of making. Lancet. 1990;1:440–1.
2. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351:781–91.
3. Committee Opinion Summary No. 640 [Internet]. Obstet. Gynecol. 2015. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00006250-201509000-00045
4. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. [Internet]. 2012;366:883–92. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22397650
5. Wang Y, Springer S, Zhang M, McMahon KW, Kinde I, Dobbyn L, et al. Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord. Proc Natl Acad Sci. 2015;112(31):9704–9. doi:10.1073/pnas.1511694112. Wang et al. investigated the use of CSF as a reservior for the detection of cfDNA brain and spinal tumor mutations using a high throughput sequencing approach. In a large cohort of 35 primary CNS tumors, the authors demonstrated that cfDNA tumor mutations can be detected in CSF when the tumor interfaces with a CSF reservior.
6. Pan W, Gu W, Nagpal S, Gephart MH, Quake SR. Brain tumor mutations detected in cerebral spinal fluid. Clin Chem. 2015;61:514–22. doi:10.1373/clinchem.2014.235457. Pan et al. is one of the first studies to primarily focus on the detection of brain tumor mutations in CSF using a high throughput sequencing approach. The authors concluded that CSF may be a superior reservior for brain tumor cfDNA when the systemic disease burden is low.
7. Lavon I, Refael M, Zelikovitch B, Shalom E, Siegal T. Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various grades. Neuro-Oncol. 2010;12:173–80.
8. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci. Transl. Med. 2014;6:224ra24. Available from: http://stm.sciencemag.org/content/6/224/224ra24.short. Bettegowda et al. investigated levels of mutant cfDNA in a large cohort of 640 patients with a variety of cancers. Interestingly, the authors observed that CNS tumors and tumors with mucinous features were detected less reliably in plasma. They hypothesized that the blood–brain barrier and mucinous layers may interfere with the shedding of tumor cfDNA into the circulation.
9. Sullivan JP, Nahed BV, Madden MW, Oliveira SM, Springer S, Bhere D, et al. Brain tumor cells in circulation are enriched for mesenchymal gene expression. Cancer Discov. 2014;4:1299–309. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4221467&tool=pmcentrez&rendertype=abstract.
10. Burgos KL, Javaherian A, Bomprezzi R, Ghaffari L, Rhodes S, Courtright A, et al. Identification of extracellular miRNA in human cerebrospinal fluid by next-generation sequencing. RNA. 2013;19:712–22. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3677285&tool=pmcentrez&rendertype=abstract.
11. Chen WW, Balaj L, Liau LM, Samuels ML, Kotsopoulos SK, Maguire CA, et al. BEAMing and droplet digital PCR analysis of mutant IDH1 mRNA in glioma patient serum and cerebrospinal fluid extracellular vesicles. Mol Ther Nucleic-Acids. 2013;2:e109. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3732870&tool=pmcentrez&rendertype=abstract.
12. Haber DA, Velculescu VE. Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer Discov. 2014;4:650–61. AACR.
13. Chen WW, Balaj L, Liau LM, Samuels ML, Kotsopoulos SK, Maguire CA, et al. BEAMing and droplet digital PCR analysis of mutant idh1 mrna in glioma patient serum and cerebrospinal fluid extracellular vesicles. Mol Ther Nucleic-Acids. 2013;2:e109.
14. Alix-Panabier̀es C, Pantel K. Circulating tumor cells: liquid biopsy of cancer. Clin Chem. 2013;59:110–8.
15. Racila E, Euhus D, Weiss AJ, Rao C, McConnell J, Terstappen LW, et al. Detection and characterization of carcinoma cells in the blood. Proc Natl Acad Sci U S A. 1998;95:4589–94. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=22534&tool=pmcentrez&rendertype=abstract.
16. Scher HI, Heller G, Molina A, Attard G, Danila DC, Jia X, et al. Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer. J Clin Oncol Am Soc Clin Oncol. 2015;33:1348–55.
17. Cohen SJ, Punt CJA, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol Am Soc Clinl Oncol. 2008;26:3213–21.
18. De Mattos-Arruda L, Cortes J, Santarpia L, Vivancos A, Tabernero J, Reis-Filho JS, et al. Circulating tumour cells and cell-free DNA as tools for managing breast cancer. Nat Rev Clin Oncol. 2013;10:377–89. Nature Publishing Group.
19. Müller C, Holtschmidt J, Auer M, Heitzer E, Lamszus K, Schulte A, et al. Hematogenous dissemination of glioblastoma multiforme. Sci Transl Med. 2014;6:247ra101. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25080476.
20. Macarthur KM, Kao GD, Chandrasekaran S, Alonso-Basanta M, Chapman C, Lustig RA, et al. Detection of brain tumor cells in the peripheral blood by a telomerase promoter-based assay. Cancer Res. 2014;74:2152–9. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4144786&tool=pmcentrez&rendertype=abstract.
21. Schwarzenbach H, Hoon DSB, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 2011;11:426–37.
22. Mandel P. Les acides nucleiques du plasma sanguin chez l’homme. CR Acad Sci Paris. 1948;142:241–3.
23. Leon SA, Shapirio B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977;37:646–50.
24. Puchhammer-Stöckl E, Popow-Kraupp T, Heinz FX, Mandl CW, Kunz C. Detection of varicella-zoster virus DNA by polymerase chain reaction in the cerebrospinal fluid of patients suffering from neurological complications associated with chicken pox or herpes zoster. J Clin Microbiol Am Soc Microbiol. 1991;29:1513–6.
25. Lakeman FD, Whitley RJ. Diagnosis of herpes simplex encephalitis: application of polymerase chain reaction to cerebrospinal fluid from brain-biopsied patients and correlation with disease. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. J Infect Dis. 1995;171:857–63.
26. Wang J-Y, Hsieh J-S, Chang M-Y, Huang T-J, Chen F-M, Cheng T-L, et al. Molecular detection of APC, K-ras, and p53 mutations in the serum of colorectal cancer patients as circulating biomarkers. World J Surg. 2004;28:721–6.
27. Shaw J a, Smith BM, Walsh T, Johnson S, Primrose L, Slade MJ, et al. Microsatellite alterations plasma DNA of primary breast cancer patients. Clin Cancer Res. 2000;6:1119–24.
28. Benesova L, Belsanova B, Suchanek S, Kopeckova M, Minarikova P, Lipska L, et al. Mutation-based detection and monitoring of cell-free tumor DNA in peripheral blood of cancer patients. Anal Biochem. 2013;433:227–34. doi:10.1016/j.ab.2012.06.018. Elsevier Inc.
29. Newman AM, Bratman S V, To J, Wynne JF, Eclov NCW, Modlin L a, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat. Med. Nature Publishing Group; 2014;20:548–54. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24705333. Newman et al. describeed an innovative approach, termed CAPP-Seq, that uses bioinformatic methods to identify common areas of recurrent mutations followed by interrogation of these areas using deep sequencing. Although described for lung cancer, this approach could have broad implications for the implementation of the liquid biopsy for other cancers since it is not patient specific.
30. Schwarzenbach H, Alix-Panabières C, Müller I, Letang N, Vendrell J-P, Rebillard X, et al. Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer. Clin Cancer Res. 2009;15:1032–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19188176.
31. Van Der Vaart M, Pretorius PJ. Circulating DNA: its origin and fluctuation. Ann N Y Acad Sci. 2008;1137:18–26.
32. Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. Nature. 2013;10:472–84. Nature Publishing Group.
33. Choi J-J, Reich CF, Pisetsky DS. The role of macrophages in the in vitro generation of extracellular DNA from apoptotic and necrotic cells. Immunology. 2005;115:55–62. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1782131&tool=pmcentrez&rendertype=abstract.
34. Diehl F, Li M, Dressman D, He Y, Shen D, Szabo S, et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A. 2005;102:16368–73. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1283450&tool=pmcentrez&rendertype=abstract.
35. Balaña C, Ramirez JL, Taron M, Multiforme G, Roussos Y, Ariza A, et al. O 6-methyl-guanine-DNA methyltransferase methylation in serum and tumor dna predicts response to temozolamide plus cisplatin in glioblastoma multiforme o 6 -methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1. 2003;9:1461–8.
36. Wong LC, Lueth M, Li X, Lau CC, Vogel H. Detection of mitochondrial dna mutations in the tumor and cerebrospinal fluid of medulloblastoma patients detection of mitochondrial dna mutations in the tumor and cerebrospinal fluid of medulloblastoma patients 1. 2003;3866–71.
37. Liu B-L, Cheng J-X, Zhang W, Zhang X, Wang R, Lin H, et al. Quantitative detection of multiple gene promoter hypermethylation in tumor tissue, serum, and cerebrospinal fluid predicts prognosis of malignant gliomas. Neuro-Oncol. 2010;12:540–8. Available from: http://neuro-oncology.oxfordjournals.org/cgi doi/10.1093/neuonc/nop064.
38. Hunter MP, Ismail N, Zhang X, Aguda BD, Lee EJ, Yu L, et al. Detection of microRNA expression in human peripheral blood microvesicles. PLoS One. 2008;3:e3694. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2577891&tool=pmcentrez&rendertype=abstract.
39. Fernandez-Mercado M, Manterola L, Larrea E, Goicoechea I, Arestin M, Armesto M, et al. The circulating transcriptome as a source of non-invasive cancer biomarkers: concepts and controversies of non-coding and coding RNA in body fluids. J. Cell. Mol. Med. 2015;XX:n/a – n/a. Available from: http://doi.wiley.com10.1111/jcmm.12625
40. El-Hefnawy T, Raja S, Kelly L, Bigbee WL, Kirkwood JM, Luketich JD, et al. Characterization of amplifiable, circulating RNA in plasma and its potential as a tool for cancer diagnostics. Clin Chem Am Assoc Clin Chem. 2004;50:564–73.
41. Lo KW, Lo YM, Leung SF, Tsang YS, Chan LY, Johnson PJ, et al. Analysis of cell-free Epstein-Barr virus associated RNA in the plasma of patients with nasopharyngeal carcinoma. Clin Chem. 1999;45:1292–4.
42. Kopreski MS, Benko FA, Kwak LW, Gocke CD. Detection of tumor messenger RNA in the serum of patients with malignant melanoma. Clin Cancer Res. 1999;5:1961–5.
43. Chen XQ, Bonnefoi H, Pelte MF, Lyautey J, Lederrey C, Movarekhi S, et al. Telomerase RNA as a detection marker in the serum of breast cancer patients. Clin Cancer Res. 2000;6:3823–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11051224.
44. Fleischhacker M, Beinert T, Ermitsch M, Seferi D, Possinger K, Engelmann C, et al. Detection of amplifiable messenger RNA in the serum of patients with lung cancer. Ann N Y Acad Sci. 2001;945:179–88. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11708476.
45. García V, García JM, Peña C, Silva J, Domínguez G, Lorenzo Y, et al. Free circulating mRNA in plasma from breast cancer patients and clinical outcome. Cancer Lett. 2008;263:312–20. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18280643.
46. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105:10513–8.
47. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol. 2008;141:672–5. Wiley Online Library.
48. Hu Z, Chen X, Zhao Y, Tian T, Jin G, Shu Y, et al. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol. 2010;28:1721–6.
49. Millholland JM, Li S, Fernandez CA, Shuber AP. Detection of low frequency FGFR3 mutations in the urine of bladder cancer patients using next-generation deep sequencing. Res Rep Urol. 2012;4:33. Dove Press.
50. Li Y, Zhou X, John MARS, Wong DTW. RNA profiling of cell-free saliva using microarray technology. J Dent Res. 2004;83:199–203. SAGE Publications.
51. Ahmed FE, Jeffries CD, Vos PW, Flake G, Nuovo GJ, Sinar DR, et al. Diagnostic microRNA markers for screening sporadic human colon cancer and active ulcerative colitis in stool and tissue. Cancer Genomics Proteomics. 2009;6:281–95. International Institute of Anticancer Research.
52. Baraniskin A, Kuhnhenn J, Schlegel U, Chan A, Deckert M, Gold R, et al. Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. Blood. 2011;117:3140–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21200023.
53. Baraniskin A, Kuhnhenn J, Schlegel U, Maghnouj A, Zöllner H, Schmiegel W, et al. Identification of microRNAs in the cerebrospinal fluid as biomarker for the diagnosis of glioma. Neuro-Oncol. 2012;14:29–33.
54. Teplyuk NM, Mollenhauer B, Gabriely G, Giese A, Kim E, Smolsky M, et al. MicroRNAs in cerebrospinal fluid identify glioblastoma and metastatic brain cancers and reflect disease activity. Neuro-Oncol. 2012;14:689–700.
55. Wei D, Wan Q, Li L, Jin H, Liu Y, Wang Y, et al. MicroRNAs as potential biomarkers for diagnosing cancers of central nervous system: a meta-analysis. Mol Neurobiol. 2014;51(3):1452–61.
56. Qu S, Guan J, Liu Y. Identification of microRNAs as novel biomarkers for glioma detection: a meta-analysis based on 11 articles. J Neurol Sci. 2015;348:181–7. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0022510X14007655.
57. Evaluating the expression levels of microRNA-10b in patients with gliomas. Available from: https://clinicaltrials.gov/ct2/show/NCT01849952
58. Brastianos PK, Carter SL, Santagata S, Cahill DP, Taylor-Weiner A., Jones RT, et al. Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets. Cancer Discov. 2015; Available from: http://cancerdiscovery.aacrjournals.org/cgi doi/10.1158/2159-8290.CD-15-0369